Application of ring B ethyoxyl silybin in preparing medicaments for treating viral hepatitis B

A technology of silibinin and ethoxylate, which is applied in the field of medicine, can solve the problems of few documents, not effectively developed and the like, and achieves the effects of convenient source, convenient source of raw materials, and simple and easy preparation method.
CN101829089BInactive Publication Date: 2012-02-01DALI UNIV
9 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
DALI UNIV
Publication Date
2012-02-01
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to application of ring B ethyoxyl silybin in preparing medicaments for treating viral hepatitis B, in particular to application of ring B ethyoxyl substituted silybin ester or a pharmaceutically acceptable salt thereof in preparing medicaments for clearing away HBsAG (Hepatitis B Surface Antigen) and HBeAg (Hepatitis B e Antigen) and suppressing the HBV (Hepatitis B Virus) DNA replication. The compound has strong activity on suppressing the HBsAG and the HBeAg, and in the presence of a concentration of 20 micrograms / milliliter, the intensities for clearing the HBsAg and the HBeAg are respectively 64.6 percent and 44.8 percent which are 4.0 times and 2.7 times of that of alpha-interferon which is a positive control medicament. In the presence of the concentration, the suppression rate of the compound on the HBV DNA is 58.1 percent which is 1.5 times of the corresponding activity of the alpha-interferon. Accordingly, the flavonolignan or the pharmaceutically acceptable salt thereof are indicated to simultaneously have strong efficacy on suppressing the HBsAg, the HBeAg and the HBV DNA and can be expected to be used for preparing non-nucleoside medicaments for treating HBV infection diseases.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the technical field of medicine, in particular, the present invention relates to a kind of silybin ester substituted by B ring ethoxy group or its pharmaceutically acceptable salt, which is used to prepare and reduce hepatitis B virus surface antigen HBsAg and hepatitis B e antigen HBeAg, inhibit Application of HBV DNA replication and medicine for treating hepatitis B virus infection. The flavonoid lignans have a potent activity of inhibiting HBsAg and HBeAg, and at a concentration of 20 micrograms / ml, the intensity of removing HBsAg and HBeAg is 64.6% and 44.8%, respectively, which are positive control drugs (10000 units / ml of α- 4.0 times and 2.7 times that of α-interferon); at this concentration, it shows an inhibition rate of 58.1% to HBV DNA, which is 1.5 times that of α-interferon. The above shows that the flavonoid lignan or its pharmaceutically acceptable salt has the effect of inhibiting HBsAg, HBeAg and HBV DNA...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More